Scholarlink

<p>This study investigates the use of RADA16 hydrogels for delivering carnosic acid (CA) in glaucoma treatment. Rheological tests at 0.5% (w/v), 1% (w/v), and 2% (w/v) concentrations showed significant elasticity, with Young’s moduli of 30.18&#xa0;Pa, 16.22&#xa0;Pa, and 26.66&#xa0;Pa, respectively. The 1% (w/v) concentration had the lowest stiffness, ideal for intravitreal injection. SEM revealed the hydrogel’s porous microstructure. The RADA16-CA system provided sustained CA release over 72&#xa0;h, peaking at 6&#xa0;h. In vitro, high CA concentrations (≥ 256&#xa0;μg/mL) were cytotoxic, but RADA16 and RADA16-CA enhanced cell proliferation. RADA16-CA demonstrated superior efficacy and biocompatibility. In an acute ocular hypertension model, RADA16-CA improved retinal health in rats by reducing retinal nerve fiber layer thickness, ROS-positive cells, and pro-inflammatory cytokines, while boosting cell survival and antioxidant activity.These findings highlight the potential of the RADA16-CA sustained-release system as an optimized approach for glaucoma treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sustained intravitreal delivery of carnosic acid by RADA16 peptide hydrogel protects the retina in acute ocular hypertension

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Hao Hu,
  • Yiyao Wang,
  • Dadong Jia,
  • Shi Luo,
  • Yi Fan Deng,
  • Ruwen Wang,
  • Xiaoyu Liu,
  • Xuelian Guo,
  • Gang Wu,
  • JingYi Sun,
  • Liang Liang

摘要

This study investigates the use of RADA16 hydrogels for delivering carnosic acid (CA) in glaucoma treatment. Rheological tests at 0.5% (w/v), 1% (w/v), and 2% (w/v) concentrations showed significant elasticity, with Young’s moduli of 30.18 Pa, 16.22 Pa, and 26.66 Pa, respectively. The 1% (w/v) concentration had the lowest stiffness, ideal for intravitreal injection. SEM revealed the hydrogel’s porous microstructure. The RADA16-CA system provided sustained CA release over 72 h, peaking at 6 h. In vitro, high CA concentrations (≥ 256 μg/mL) were cytotoxic, but RADA16 and RADA16-CA enhanced cell proliferation. RADA16-CA demonstrated superior efficacy and biocompatibility. In an acute ocular hypertension model, RADA16-CA improved retinal health in rats by reducing retinal nerve fiber layer thickness, ROS-positive cells, and pro-inflammatory cytokines, while boosting cell survival and antioxidant activity.These findings highlight the potential of the RADA16-CA sustained-release system as an optimized approach for glaucoma treatment.